

Dear friends of PharmaLundensis

PharmaLundensis AB

PharmaLundensis develops new, effective and gentle drugs to bind and excrete heavy metals such as mercury, lead and cadmium from the body. We believe that several of our most common disorders are caused by these metals, such as the lung diseases COPD and chronic bronchitis, and also severe depression. Additionally, under the subsidiary CleanTech Lund, we market our proprietary Minievaporator for the purification of liquid hazardous waste from various companies.

Recently, we received very encouraging results from a pilot toxicology study where a group of mice receiving high doses of Phal-501 for three days exhibited no adverse effects whatsoever. Histological analyses of the mice's mucosa from both the small and large intestines showed completely normal results, with no signs of inflammation or irritation. The mucosa of the gastrointestinal tract is the only tissue that comes into contact with Phal-501 as the substance never enters the bloodstream. These animal tests strongly suggest that Phal-501 will be very well tolerated by humans. We continue preparations for the first clinical study on chronic bronchitis and then COPD.

Another positive news about Phal-501 is the announcement from the European Patent Office (EPO) that our PCT application contains structures that meet all their requirements for obtaining a patent. This PCT application can now form the basis for patents in most countries of the world.

The Minievaporator is also making good progress. We are currently conducting intensive sales of the Minievaporator within Cleantech Lund following two tracks: via direct sales of machinery to companies

producing chemical waste, and a sale of the entire Minievaporator project to a large company. Discussions are ongoing with major companies about selling the entire Minievaporator project. We feel that their interest is considerable. In parallel, discussions are underway with several smaller companies regarding selling individual machines. We estimate that there could be hundreds of thousands of companies in Europe running a business that could benefit from our machine. Through larger production series, we can set a reasonable price that still gives PharmaLundensis a good profit. If we conclude agreements with larger companies on the sale of the entire project, it can generate substantial revenue to PharmaLundensis already by spring. Conversely, if we decide to focus on selling to many small companies, it can yield good revenue over many years.

Phal-501 can be a great drug that has the potential to change the lives of many seriously ill patients. Capital must now be secured for further development. I will personally subscribe to the issue for at least SEK 200,000. I encourage those of you who are interested in a new and effective COPD drug to also consider contributing to the funding. Please note that it is only by subscribing to PharmaLundensis' new issues that you can contribute to our research! If you buy shares on the stock exchange instead, the money will not benefit PharmaLundensis.

A warm welcome to subscribe to PharmaLundensis' new share issue!

Dr Staffan Skogvall
Chief Executive Officer

"Recently, we received very encouraging results from a pilot toxicology study where a group of mice receiving high doses of Phal-501 for three days exhibited no adverse effects whatsoever."



You can subscribe for shares without preferential rights by going to mangold.se/aktuella-emissioner/ and following the instructions.

Personal assistance can be obtained from Mangold by e-mail: emissioner@mangold.se and phone: +46 (0)8-5030 1595.

You can also download the subscription form "SUBSCRIPTION OF SHARES WITHOUT SUPPORT OF SUBSCRIPTION RIGHTS IN PHARMA LUNDENSIS AB" on PharmaLundensis' website, fill it in and send it to Mangold. The page is clickable and can be typed on the computer.